Shikiko Ueno

568 total citations
30 papers, 420 citations indexed

About

Shikiko Ueno is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Shikiko Ueno has authored 30 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Hematology. Recurrent topics in Shikiko Ueno's work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (6 papers) and Renal and related cancers (5 papers). Shikiko Ueno is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (6 papers) and Renal and related cancers (5 papers). Shikiko Ueno collaborates with scholars based in Japan, United States and Singapore. Shikiko Ueno's co-authors include Yutaka Okuno, Hiroaki Mitsuya, Hiro Tatetsu, Hiroyuki Hata, Daniel G. Tenen, Masamichi Takahashi, S Yoshimatsu, Shinya Endo, Yasuo Yamashita and Motohiro Takeya and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

Shikiko Ueno

27 papers receiving 410 citations

Peers

Shikiko Ueno

PRM

HEMAT

ONCOL

RNMI

F Desangles France

Thelma R. Tennant United States

Salina Tsai United States

Yasunori Harada Japan

Carolina Moreno Brazil

Zachary Zimmerman United States

Suzanne Bertrand France

Jeffrey R. Sawyer United States

Anna Antenucci Italy

Xiaohong Jia China

F Desangles France

Shikiko Ueno

339 ×1.3

90 ×0.6

PRM

206 ×2.9

HEMAT

77 ×1.4

ONCOL

39 ×0.8

RNMI

Citations per year, relative to Shikiko Ueno Shikiko Ueno (= 1×) peers F Desangles

Countries citing papers authored by Shikiko Ueno

Since Specialization

Citations

This map shows the geographic impact of Shikiko Ueno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shikiko Ueno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shikiko Ueno more than expected).

Fields of papers citing papers by Shikiko Ueno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shikiko Ueno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shikiko Ueno. The network helps show where Shikiko Ueno may publish in the future.

Co-authorship network of co-authors of Shikiko Ueno

This figure shows the co-authorship network connecting the top 25 collaborators of Shikiko Ueno. A scholar is included among the top collaborators of Shikiko Ueno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shikiko Ueno. Shikiko Ueno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tatetsu, Hiro, Koji Kato, Atsushi Wada, et al.. (2025). Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. International Journal of Hematology. 122(6). 815–819.

Sonoki, Takashi, Yasunori Ueda, Shikiko Ueno, et al.. (2024). GUIDELINE FOR THE USE OF RED BLOOD CELL PRODUCTS BASED ON SCIENTIFIC EVIDENCE (REVISION THIRD EDITION). Japanese Journal of Transfusion and Cell Therapy. 70(6). 579–596.

Fujimoto, Yuki, Shikiko Ueno, Kazutaka Oda, et al.. (2021). Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. Cancers. 13(22). 5674–5674.

Tatetsu, Hiro, Myriam Armant, Fei Wang, et al.. (2019). Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology. 75. 53–63.e11. 4 indexed citations

Ueno, Shikiko, Yawara Kawano, Yoshitaka Kikukawa, et al.. (2019). [Spontaneous remission of acquired factor XIII inhibitor concurrent to development of IgA-λ type multiple myeloma].. PubMed. 60(10). 1443–1448. 1 indexed citations

Nishimura, Nao, Mohamed O. Radwan, Masayuki Amano, et al.. (2019). Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells. Cancer Science. 110(10). 3275–3287. 26 indexed citations

Endo, Shinya, Nao Nishimura, Yawara Kawano, et al.. (2018). MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells. Biochemical and Biophysical Research Communications. 507(1-4). 246–252. 6 indexed citations

Nishimura, Nao, Shinya Endo, Shikiko Ueno, et al.. (2017). A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo. Biochemical and Biophysical Research Communications. 486(4). 916–922. 2 indexed citations

Tokunaga, Kenji, Shikiko Ueno, Yoshitaka Kikukawa, et al.. (2017). Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/<i>RUNX1-RUNX1T1</i> Rearrangement. Internal Medicine. 57(4). 563–568. 6 indexed citations

10.

Nishimura, Nao, Shikiko Ueno, Shinya Endo, et al.. (2017). PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene. 36(31). 4481–4497. 27 indexed citations

11.

Kikukawa, Yoshitaka, Hiroyuki Hata, Mitsuharu Ueda, et al.. (2016). Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone. Internal Medicine. 55(18). 2707–2712. 3 indexed citations

12.

Endo, Shinya, Masayuki Amano, Nao Nishimura, et al.. (2015). Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells. Biochemical and Biophysical Research Communications. 469(2). 236–242. 12 indexed citations

13.

Ueno, Shikiko, Jiayun Lu, Ailing Li, et al.. (2014). Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: Mechanism, function, and implication for a potential novel therapeutic target. Experimental Hematology. 42(4). 307–316.e8. 27 indexed citations

14.

Gao, Chong, Nikki R. Kong, Ailing Li, et al.. (2012). SALL4 is a key transcription regulator in normal human hematopoiesis. Transfusion. 53(5). 1037–1049. 40 indexed citations

15.

Tatetsu, Hiro, Shikiko Ueno, Hiroyuki Hata, et al.. (2007). Down-regulation of PU.1 by Methylation of Distal Regulatory Elements and the Promoter Is Required for Myeloma Cell Growth. Cancer Research. 67(11). 5328–5336. 41 indexed citations

16.

Yamashita, Yasuo, Shikiko Ueno, O Makita, et al.. (1993). Hyperechoic renal tumors: anechoic rim and intratumoral cysts in US differentiation of renal cell carcinoma from angiomyolipoma.. Radiology. 188(1). 179–182. 56 indexed citations

17.

Takahashi, Masamichi, Shikiko Ueno, S Yoshimatsu, et al.. (1992). Gastrointestinal examinations with digital radiography.. Radiographics. 12(5). 969–978. 16 indexed citations

18.

Yamashita, Yo‐ichi, M Takahashi, Osamu Watanabe, et al.. (1992). Small renal cell carcinoma: pathologic and radiologic correlation.. Radiology. 184(2). 493–498. 65 indexed citations

19.

Fukui, Kiichi, et al.. (1986). Automatic reregistration for correction of localized misregistration artifacts in digital subtraction angiography of the head and neck.. PubMed. 369. 281–4. 7 indexed citations

20.

Takahashi, Masashi, et al.. (1982). [Diagnosis of cardiovascular diseases by digital fluoroscopic angiography].. PubMed. 27(9). 887–95. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact